Gene: CYP2F1

1572
C2F1|CYP2F|CYPIIF1
cytochrome P450 family 2 subfamily F member 1
protein-coding
19q13.2
Ensembl:ENSG00000197446 MIM:124070 Vega:OTTHUMG00000167412 UniprotKB:P24903
NG_007930.1
PubMed
0   ANCO-SNPs
ND
5   
NA (AD)  NA (ND)   (Frontal_Cortex)
9.296e-1 (AD)  8.224e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
TMPRSS120.712
DEFB1160.704
OR8H10.702
LINC004300.68
DEFB1180.668
CRISP10.667
DEFB1210.665
OR4Q20.663
OR5A20.663
TRIM490.642

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
HPR-0.271
NWD1-0.249
MYBPC1-0.221
ENDOU-0.217
NTSR2-0.217
HSPB2-0.211
ALDH4A1-0.21
RNF182-0.21
FXYD3-0.206
LRP4-0.202

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0330201-aminobenzotriazole1-aminobenzotriazole inhibits the reaction [Skatole results in increased expression of CYP2F1 mRNA]20187624
C0977453-methyleneindolenine[CYP2F1 protein results in increased metabolism of Skatole] which results in increased chemical synthesis of 3-methyleneindolenine20187624
C011512alpha-naphthoflavone[alpha-naphthoflavone binds to and results in decreased activity of AHR protein] inhibits the reaction [Skatole results in increased expression of CYP2F1 mRNA]20187624
D001554BenzeneCYP2F1 protein results in increased hydroxylation of Benzene15122651
D004958EstradiolEstradiol results in decreased expression of CYP2F1 mRNA17982697
D004958Estradiol[Parathion co-treated with Estradiol] results in increased expression of CYP2F1 mRNA17982697
C006780bisphenol Abisphenol A results in decreased expression of CYP2F1 mRNA25181051
D0151248-Bromo Cyclic Adenosine Monophosphate8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CYP2F1 mRNA22079614
D003513CycloheximideCycloheximide inhibits the reaction [Skatole results in increased expression of CYP2F1 mRNA]20187624
C089595cylindrospermopsincylindrospermopsin results in decreased expression of CYP2F1 mRNA23726867
D003609DactinomycinDactinomycin inhibits the reaction [Skatole results in increased expression of CYP2F1 mRNA]20187624
D005472FluorouracilFluorouracil affects the expression of CYP2F1 mRNA16584549
C419708gefitinibgefitinib results in decreased expression of CYP2F1 mRNA16685379
D012862Skatole1-aminobenzotriazole inhibits the reaction [Skatole results in increased expression of CYP2F1 mRNA]20187624
D012862Skatole[alpha-naphthoflavone binds to and results in decreased activity of AHR protein] inhibits the reaction [Skatole results in increased expression of CYP2F1 mRNA]20187624
D012862SkatoleCycloheximide inhibits the reaction [Skatole results in increased expression of CYP2F1 mRNA]20187624
D012862SkatoleCYP2F1 protein results in increased metabolism of and results in increased activity of Skatole20795680
D012862SkatoleCYP2F1 protein results in increased metabolism of Skatole20187624
D012862Skatole[CYP2F1 protein results in increased metabolism of Skatole] which results in increased chemical synthesis of 3-methyleneindolenine20187624
D012862SkatoleDactinomycin inhibits the reaction [Skatole results in increased expression of CYP2F1 mRNA]20187624
D012862SkatoleSkatole metabolite results in increased expression of CYP2F1 mRNA20187624
C517284monomethyl phthalatemonomethyl phthalate affects the expression of CYP2F1 mRNA26924002
C031721naphthaleneCYP2F1 protein affects the reaction [CYP2A13 protein results in increased metabolism of naphthalene]28599267
C031721naphthalene[CYP2F1 protein co-treated with CYP2A13 protein] results in increased metabolism of naphthalene28599267
D010278Parathion[Parathion co-treated with Estradiol] results in increased expression of CYP2F1 mRNA17982697
D010278ParathionParathion results in increased expression of CYP2F1 mRNA17982697
D010634PhenobarbitalPhenobarbital results in increased expression of CYP2F1 mRNA22258563
D010634PhenobarbitalPhenobarbital results in increased expression of CYP2F1 mRNA15596064
D011285Pregnenolone CarbonitrilePregnenolone Carbonitrile results in increased expression of CYP2F1 mRNA15596064
D012293RifampinRifampin results in decreased expression of CYP2F1 mRNA22258563
D015032ZincZinc deficiency results in increased expression of CYP2F1 mRNA18356318

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0004497monooxygenase activity-TAS-  
GO:0005506iron ion binding-IEA-  
GO:0008392arachidonic acid epoxygenase activity-IBA21873635  
GO:0008395steroid hydroxylase activity-IBA21873635  
GO:0016712oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen-IBA21873635  
GO:0016712oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen-IDA10383923  
GO:0019825oxygen binding-IEA-  
GO:0020037heme binding-IBA21873635  
GO:0020037heme binding-IEA-  
GO:0070330aromatase activity-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0006082organic acid metabolic process-IBA21873635  
GO:0006805xenobiotic metabolic process-IBA21873635  
GO:0006805xenobiotic metabolic process-TAS-  
GO:0009636response to toxic substance-IEA-  
GO:0018931naphthalene metabolic process-IBA21873635  
GO:0018931naphthalene metabolic process-IDA10383923  
GO:0018979trichloroethylene metabolic process-IEA-  
GO:0042738exogenous drug catabolic process-IBA21873635  
GO:0055114oxidation-reduction process-IBA21873635  
GO:0055114oxidation-reduction process-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005737cytoplasm-IBA21873635  
GO:0005789endoplasmic reticulum membrane-TAS-  
GO:0031090organelle membrane-IEA-  
GO:0043231intracellular membrane-bounded organelle-IBA21873635  
GO:0043231intracellular membrane-bounded organelle-IDA10383923  
KEGG ID KEGG Term
hsa00980Metabolism of xenobiotics by cytochrome P450
Reactome ID Reactome Term Evidence
R-HSA-1430728MetabolismTAS
R-HSA-211859Biological oxidationsTAS
R-HSA-211897Cytochrome P450 - arranged by substrate typeTAS
R-HSA-211935Fatty acidsTAS
R-HSA-211945Phase I - Functionalization of compoundsTAS
R-HSA-211981XenobioticsTAS
R-HSA-211999CYP2E1 reactionsTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
25505599Gene expression analysis of membrane transporters and drug-metabolizing enzymes in the lung of healthy and COPD subjects. (2014 Aug)Berg TPharmacol Res Perspect
8694864Detection of cytochrome P450 gene expression in human placenta in first trimester of pregnancy. (1996 Jul 26)Hakkola JBiochem Pharmacol
8845177Xenobiotic metabolism enzyme gene expression in human bronchial epithelial and alveolar macrophage cells. (1996 Mar)Willey JCAm J Respir Cell Mol Biol
22232929[Polymorphic markers of the CYP1B1 (4326C > G), CYP2F1 (c.14_15insC), CYP2J2 (-76G > T), and CYP2S1 (13106C > T and 13255A > G) genes and genetic predisposition to chronic respiratory diseases induced by smoking and occupational factors]. (2011 Oct)Akhmadishina LAGenetika
8619884Expression of xenobiotic-metabolizing cytochrome P450 forms in human full-term placenta. (1996 Feb 23)Hakkola JBiochem Pharmacol